



RADIOPHARM THERANOSTICS RAISES A\$20M SEED CAPITAL FOR WORLD-CLASS NUCLEAR MEDICINE TECHNOLOGIES

- Capital raising attracts strong support from institutional & sophisticated high net worth investors
- Radiopharm Theranostics is focused on development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs
- Highly prospective portfolio of four distinct & clearly differentiated platform technologies
- Pipeline candidate selection based on their potential to be *First to Market* or *Best in Class* in the respective therapeutic applications
- Three phase two and five phase one trials underway across the portfolio with a total of ~127 patients dosed to date
- Attractive license agreements, robust & long IP protection
- Key executives secured including Prof David Mozley as CMO and Dr Thom Tulip as CTO, with CEO announcement in the near term
- The company is considering additional future funding pathways

Radiopharm Theranostics, developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has raised A\$20 million via convertible notes through Bell Potter and Baker Young, to progress a highly prospective portfolio of radiopharmaceutical assets for diagnostic and therapeutic applications.

The company received strong demand for the offer, thereby increasing the raise to \$20m from the original target of \$15m. A range of institutional and sophisticated investors have joined the register as part of the capital raising.

Within the portfolio, Radiopharm Theranostics has five phase one clinical trials and three phase two trials underway, with ~127 patients dosed across three of the four assets to date.

Radiopharmaceuticals are radioactive drugs that can either act as a diagnostic, allowing physicians to see and to measure disease within the body, or as a therapeutic where high energy particles are emitted to treat cancer and other diseases.

Radiopharm Theranostics has a balanced portfolio of four distinct & highly differentiated platforms, spanning peptides, small molecules and monoclonal antibodies and addressing about 75% of the causes of death from cancer:

- NanoMabs: Phase 1 & Phase 2 trials underway for diagnostic & therapeutics in solid tumours (gastric, breast & lung cancer);
- 18F-FPIA: Phase 1 & Phase 2 trials underway for diagnostic in solid tumours (kidney & gliomas);
- avβ6 Integrins: Phase 1 underway for diagnostics in solid tumours (pancreatic, head & neck cancers, & pre-clinical studies underway for therapeutic use);
- hu PSA antibody: Pre-clinical studies underway for diagnostic & therapeutic use.

The asset portfolio has been secured under commercially attractive license arrangements. Each technology in the portfolio is backed by a broad and robust intellectual property portfolio, with long patent lives.

Radiopharm Theranostics, founded by the experienced Australian life sciences industry figure Paul Hopper, has assembled a team of industry experts to lead development of the portfolio.

Professor David Mozley, until recently, Professor of Nuclear Medicine at Cornell University, has joined as Chief Medical Officer. He also brings senior experience at Merck & Co and Eli Lilly.

Dr Thom Tulip has been appointed Chief Technical Officer, having spent more than 25 years in the development and commercialisation of radiopharmaceuticals and imaging agents. He has served in senior leadership roles at Navidea BioPharmaceuticals Inc, Alseres Pharmaceuticals, Lantheus Medical Imaging (LMI), Bristol Myers Squibb (BMS), and DuPont.

A CEO with deep global radiopharmaceutical experience has been appointed and is expected to be announced in the near term.

"I am thrilled to be able to combine a range of outstanding assets with highly credentialled management in a sector that has attracted an intense level of interest in recent years," Mr Hopper said.

"The funds we've been able to bring in as part of this capital raising will allow us to further develop our portfolio unimpeded, while building out the executive team as we consider additional funding options moving forward.

"I'd like to thank our new shareholders for their support and look forward to delivering value to our investors while ultimately commercialising radiopharmaceutical technologies that improves patient outcomes."

The use of funds from the capital raising will include licensing and development of each of the four technology platforms, as well as working capital for the company.

There has been an extreme level of investor interest in the radiopharmaceutical sector in recent years and significant M&A activity globally including within the key market of China. Several key transactions have led this activity including the Novartis acquisition of Advanced Accelerator Applications and Endocyte for \$3.9 billion and \$2.1 billion respectively.

For more information:

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>